Business
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot
MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated to Complete Patien...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-PilotMAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated to Complete Patient Recruitment during Q1 2024Toronto, Ontario--(Newsfile Corp. - December 5, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (\"Cardiol\" or the \"Company\"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that Massachusetts General Hospital (\"Mass General\") has been initiated and is eligible to enroll patients in MAvERIC-Pilot, the Company's Phase II open-label pilot study, investigating the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis. In addition to standard safety assessments, the study is designed to evaluate improvement in objective measures of this rare disease, and during an extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids, while taking CardiolRx™ and to assess freedom from pericarditis recurrence.\"We are delighted to have the world-renowned Massachusetts General Hospital contributing to our MAvERIC-Pilot study enrollment,\" commented Dr. Andrew Hamer, Cardiol Therapeutics' Chief Medical Officer and Head of Research & Development. \"Mass General has been consistently ranked as a top hospital in the United States and has the largest hospital-based research program in the country. We look forward to the support of Mass General's clinicians and participating patients towards reaching full enrollment in this ground-breaking study.\"MAvERIC-Pilot is enrolling 25 patients at eight prominent medical research centers in the United States that specialize in pericarditis care. The study recently surpassed 50% of its enrollment objective and is anticipated to complete patient recruitment during Q1 2024. The study Chairman is Allan L. Klein, MD, Director of the Center of Pericardial Diseases and Professor of Medicine, Heart and Vascular Institute, at the Cleveland Clinic. The primary efficacy endpoint is the change, from baseline to 8 weeks, in patient-reported pericarditis pain usi...